BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16903935)

  • 1. Clinical value of vesical leukoplakia and evaluation of the neoplastic risk by mutation analyses of the tumor suppressor gene TP53.
    Staack A; Schlechte H; Sachs M; Kristiansen G; Burkhardt M; Schnorr D
    Int J Urol; 2006 Aug; 13(8):1092-7. PubMed ID: 16903935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders.
    Ogmundsdóttir HM; Hilmarsdóttir H; Björnsson J; Holbrook WP
    J Oral Pathol Med; 2009 Oct; 38(9):716-21. PubMed ID: 19473449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
    Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
    Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
    Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
    Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers.
    Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
    Clin Cancer Res; 1996 Oct; 2(10):1795-800. PubMed ID: 9816132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
    Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
    Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
    Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
    Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method.
    Masuda A; Kikuchi YY; Kawamura N
    Tokai J Exp Clin Med; 2000 Jun; 25(2):69-77. PubMed ID: 11127510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
    Gupta NP; Sharma N; Kumar R
    Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microsatellite instability in urine sediments from patients with transitional cell carcinoma of bladder and its clinical value].
    Lü Y; Tang D; Yu L; Ding Y; Liu L; Guo Y
    Zhonghua Wai Ke Za Zhi; 2000 Apr; 38(4):294-6. PubMed ID: 12828175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.